(Q39682105)

English

Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors

scientific article published on March 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

retracted paper

1 reference

Retraction Watch

29 December 2023

https://doi.org/10.1016/j.lungcan.2023.107226

Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Fortunato Ciardiello

9

object named as

Fortunato Ciardiello

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

author name string

Floriana Morgillo

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Elena D'Aiuto

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Teresa Troiani

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Erika Martinelli

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Tina Cascone

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Raffaele De Palma

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Michele Orditura

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Ferdinando De Vita

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

publication date

1 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

71

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

283-290

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Roles of CHOP/GADD153 in endoplasmic reticulum stress

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Overview of cell death signaling pathways

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Targeting the cell death-survival equation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

A trip to the ER: coping with stress

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

EGFR antagonists in cancer treatment

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Approval summary for bortezomib for injection in the treatment of multiple myeloma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Proteasome inhibitor, bortezomib, for myeloma and lymphoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

The potential of proteasome inhibitors in cancer therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Identifiers

10.1016/J.LUNGCAN.2010.06.005

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39682105&oldid=2043535971"